Onco Wiki / Maladie

Méningiome

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-MENINGIOMA
TypeMaladie
Alias
WHO grade I/II/III meningiomaméningiome anaplastiqueMéningiome atypiqueméningiome intracrânienméningiome spinalМенінгіома
Étatreviewed 2026-05-04 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-EANO-MENINGIOMA-2024 SRC-NCCN-CNS-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology9530/0
icd_o_3_topography["C70"]
icd_10D32
who_classificationWHO Classification of Tumours of the CNS 5th ed (2021): Meningioma (grades 1–3)

Capacités

Notes

Most meningiomas are WHO grade I (benign) and cured by gross total resection. Grade II (atypical) and grade III (anaplastic) have high recurrence rates and limited systemic options. NF2 loss is the most common molecular event; NF2-associated meningiomas often harbor co-occurring SMARCB1/SMARCA4 alterations in aggressive subtypes. Targeted therapy: AKT1-mutant meningioma → AKT inhibitors (capivasertib, ipatasertib) in phase II trials. SMO-mutant meningioma → vismodegib (case series). Selumetinib for NF2-associated plexiform neurofibroma has shown activity (FDA-approved in NF1 pediatric context) but NF2-meningioma selumetinib data is limited. Hormonal agents (progesterone receptor antagonists) not proven effective in trials. Bevacizumab used off-label for recurrent/progressive grade II-III based on small trials.

Utilisé par

Pertinence thérapeutique

Algorithmes

Indication

Procédures

Questionnaires

Signal d’alerte